Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives

References

• CardosoF, KyriakidesS, OhnoS, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1674. doi:10.1093/annonc/mdz189.31236598
   PubMed Web of Science ®Google Scholar
• DeeksED. Fulvestrant: a review in advanced breast cancer not previously treated with endocrine therapy. Drugs. 2018;78(1):131–137. doi:10.1007/s40265-017-0855-529270913
   PubMed Web of Science ®Google Scholar
• RobertsonJFR, BondarenkoIM, TrishkinaE, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997–3005. doi:10.1016/S0140-6736(16)32389-327908454
   PubMed Web of Science ®Google Scholar
• RobertsonJF, Llombart-CussacA, RolskiJ, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol. 2009;27(27):4530–4535. doi:10.1200/JCO.2008.21.113619704066
   PubMed Web of Science ®Google Scholar
• JohnstonSR, KilburnLS, EllisP, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol. 2013;14(10):989–998. doi:10.1016/S1470-2045(13)70322-X23902874
   PubMed Web of Science ®Google Scholar
• PereyL, ParidaensR, HawleH, et al. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol. 2007;18(1):64–69. doi:10.1093/annonc/mdl34117030543
   PubMed Web of Science ®Google Scholar
• CristofanilliM, TurnerNC, BondarenkoI, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2- metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–439. doi:10.1016/S1470-2045(15)00613-026947331
   PubMed Web of Science ®Google Scholar
• SharplessNE, SherrCJ. Forging a signature of in vivo senescence. Nat Rev Cancer. 2015;15:397–408. doi:10.1038/nrc396026105537
   PubMed Web of Science ®Google Scholar
• NaritaM, NunezS, HeardE, et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 2003;113:703–716. doi:10.1016/S0092-8674(03)00401-X12809602
   PubMed Web of Science ®Google Scholar
• FinnRS, DeringJ, ConklinD, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11:R77. doi:10.1186/bcr241919874578
   PubMed Web of Science ®Google Scholar
• FinnRS, CrownJP, LangI, et al. The cyclindependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptorpositive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised Phase 2 study. Lancet Oncol. 2015;16:25–35. doi:10.1016/S1470-2045(14)71159-325524798
   PubMed Web of Science ®Google Scholar
• HortobagyiGN, StemmerSM, BurrisHA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738–1748. doi:10.1056/NEJMoa160970927717303
   PubMed Web of Science ®Google Scholar
• GoetzMP, ToiM, CamponeM, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638–3646. doi:10.1200/JCO.2017.75.615528968163
   PubMed Web of Science ®Google Scholar
• FinnRS, MartinM, RugoHS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925–1936. doi:10.1056/NEJMoa160730327959613
   PubMed Web of Science ®Google Scholar
• RobertsonJF, NicholsonRI, BundredNJ, et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res. 2001;61:6739–6746.11559545
   PubMed Web of Science ®Google Scholar
• RobertsonJ, HarrisonM. Fulvestrant: pharmacokinetics and pharmacology. Br J Cancer. 2004;90(Suppl 1):S7–S10. doi:10.1038/sj.bjc.660163015094758
   PubMed Web of Science ®Google Scholar
• WakelingAE, BowlerJ. Steroidal pure antioestrogens. J Endocrinol. 1987;112:R7–R10. doi:10.1677/joe.0.112R0073559447
   PubMed Web of Science ®Google Scholar
• WakelingAE, DukesM, BowlerJ. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51:3867–3873.1855205
   PubMed Web of Science ®Google Scholar
• ZhangX, DiazMR, YeeD. Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells. Breast Cancer Res Treat. 2013;139:351–360. doi:10.1007/s10549-013-2541-y23686416
   PubMed Web of Science ®Google Scholar
• Di LeoA, JerusalemG, PetruzelkaL, et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst. 2014;106(1):djt337. doi:10.1093/jnci/djt33724317176
   PubMedGoogle Scholar
• RugoHS, RumbleRB, MacraeE, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: american Society of Clinical Oncology guideline. J Clin Oncol. 2016;34:3069–3103. doi:10.1200/JCO.2016.67.148727217461
   PubMed Web of Science ®Google Scholar
• PoggioF, LambertiniM, BlondeauxE, et al. Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients. Expert Rev Clin Pharmacol. 2016;9:1153–1161. doi:10.1080/17512433.2016.121524327545815
   PubMed Web of Science ®Google Scholar
• PritchardKI, ChiaSK, SimmonsC, et al. Enhancing endocrine therapy combination strategies for the treatment of postmenopausal HR+/HER2− advanced breast cancer. Oncologist. 2017;22:12–24. doi:10.1634/theoncologist.2016-018527864574
   PubMed Web of Science ®Google Scholar
• LiJ, WangZ, ShaoZ. Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: a review. Cancer Med. 2019;8(5):1943–1957. doi:10.1002/cam4.2019.8.issue-531004402
   PubMed Web of Science ®Google Scholar
• SpringLM, WanderSA, ZangardiM, BardiaA. CDK 4/6 inhibitors in breast cancer: current controversies and future directions. Curr Oncol Rep. 2019;21(3):25. doi:10.1007/s11912-019-0769-330806829
   PubMed Web of Science ®Google Scholar
• TurnerNC, RoJ, AndréF, et al. Palbociclib in hormone- receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209–219. doi:10.1056/NEJMoa150527026030518
   PubMed Web of Science ®Google Scholar
• TurnerNC, SlamonDJ, RoJ, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–1936. doi:10.1056/NEJMoa181052730345905
   PubMed Web of Science ®Google Scholar
• SledgeGW, ToiM, NevenP, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35:2875–2884. doi:10.1200/JCO.2017.73.758528580882
   PubMed Web of Science ®Google Scholar
• SledgeGWJr, ToiM, NevenP, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 2019. doi:10.1001/jamaoncol.2019.4782
   PubMed Web of Science ®Google Scholar
• SlamonDJ, NevenP, ChiaS, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36:2465–2472. doi:10.1200/JCO.2018.78.990929860922
   PubMed Web of Science ®Google Scholar
• SlamonDJ, NevenP, ChiaS, et al. Overall survival results from the phase III MONALEESA-3 study of fulvestrant ± ribociclib in postmenopausal patients with HR+/HER2− advanced breast cancer. Ann Oncol. 2019;30:v856–v857. doi:10.1093/annonc/mdz394.007
   Web of Science ®Google Scholar
• AsgharU, WitkiewiczAK, TurnerNC, KnudsenES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14:130–146. doi:10.1038/nrd450425633797
   PubMed Web of Science ®Google Scholar
• MalumbresM, SotilloR, SantamaríaD, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell. 2004;118:493–504. doi:10.1016/j.cell.2004.08.00215315761
   PubMed Web of Science ®Google Scholar
• GelbertLM, CaiS, LinX, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle- dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014;32:825–837. doi:10.1007/s10637-014-0120-724919854
   PubMed Web of Science ®Google Scholar
• HortobagyiGN, StemmerSM, BurrisHA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541–1547. doi:10.1093/annonc/mdy15529718092
   PubMed Web of Science ®Google Scholar
• DicklerMN, TolaneySM, RugoHS, et al. MONARCH 1, A phase II study of Abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR +/HER2 − metastatic breast cancer. Clin Cancer Res. 2017;23:5218–5224. doi:10.1158/1078-0432.CCR-17-075428533223
   PubMed Web of Science ®Google Scholar
• GarrigaJ, GranaX. CDK9 inhibition strategy defines distinct sets of target genes. BMC Res Notes. 2014;7:301. doi:10.1186/1756-0500-7-30124886624
   PubMedGoogle Scholar
• MarraA, CuriglianoG. Are all cyclin-dependent kinases 4/6 inhibitors created equal?NPJ Breast Cancer. 2019;29(5):27. doi:10.1038/s41523-019-0121-y
   Web of Science ®Google Scholar
• CoronaSP, GeneraliD. Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer. Drug Des Devel Ther. 2018;12:321–330. doi:10.2147/DDDT.S137783
   PubMed Web of Science ®Google Scholar
• VermaS, BartlettCH, SchnellP, et al. Palbociclib in combination with fulvestrant in women with hormone receptor-positive/HER2- Negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, Phase III study (PALOMA-3). Oncologist. 2016;21(10):1165–1175. doi:10.1634/theoncologist.2016-009727368881
   PubMed Web of Science ®Google Scholar
• McDonnellDP, WardellSE, NorrisJD. Oral selective estrogen receptor downregulators (SERDs), a breakthrough endocrine therapy for breast cancer. J Med Chem. 2015;58:4883–4887. doi:10.1021/acs.jmedchem.5b0076026039356
   PubMed Web of Science ®Google Scholar
• MartinLA, PancholiS, SimigdalaN, et al. Abstract P4-04-09: new oral SERD elacestrant (RAD1901) shows efficacy in breast cancer models harbouring ESR1 mutations and enhances the antiproliferative activity of mTORC1 and CDK4/6 inhibitors. Cancer Res. 2018;78:P4-04–09.
   Web of Science ®Google Scholar
• DeMicheleA, ClarkAS, TanKS, et al. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res. 2015;21:995–1001. doi:10.1158/1078-0432.CCR-14-225825501126
   PubMed Web of Science ®Google Scholar